ClinicalTrials.gg

Program

filgotinib

Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.

Furthest: phase 3, since Sep 22, 201646 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lakefront Biotherapeutics NV230 open or runningphase 3since Sep 22, 2016Aug 10, 2010none ahead
Gilead Sciences160 open or runningphase 3since Aug 17, 2016Aug 17, 2016none ahead
Alfasigma74 open or runningphase 3since Sep 22, 2016Sep 22, 2016Jun 2027phase 3 · NCT07554495

Also a collaborator on its studies: Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Aug 10, 2010.

  1. Jun 30, 2017Phase 2 study in Noninfectious UveitisGilead Sciences · NCT03207815 · 74 enrolled · United States, Australia, Canada and more
  2. Sep 14, 2017Phase 2 study in Lupus Membranous NephropathyGilead Sciences · NCT03285711 · 9 enrolled · United States
  3. Oct 20, 2017Phase 2 study in Arthritis, PsoriaticLakefront Biotherapeutics NV · NCT03320876 · 122 enrolled · Belgium, Bulgaria, Czechia and more
  4. Jan 25, 2018Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT03417778 · 20 enrolled · United States, Germany, New Zealand
  5. Apr 19, 2019Phase 2 study in Arthritis, RheumatoidLakefront Biotherapeutics NV · NCT03926195 · 109 enrolled · Bulgaria, Czechia, Estonia and more
  6. Oct 2, 20192 phase 3 studies in Arthritis, PsoriaticGilead Sciences · NCT04115839, NCT04115748
  7. Jul 20, 20202 phase 3 studies in Spondylitis, AnkylosingGilead Sciences · NCT04483700, NCT04483687
  8. Oct 23, 2020Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT04608344 · 27 enrolled · United States
  9. Jul 26, 2022Phase 3 study in Colitis, UlcerativeLakefront Biotherapeutics NV · NCT05479058 · 22 enrolled · United States, Belgium, Czechia and more
  10. Mar 14, 2023Phase 3 study in Axial SpondyloarthritisAlfasigma · NCT05785611 · 495 enrolled · Belgium, Bulgaria, Czechia and more
  11. Sep 11, 2023Phase 1 study in BioavailabilityLakefront Biotherapeutics NV · NCT06043739 · 12 enrolled · Canada
  12. Jan 4, 2024Phase 1 study in Arthritis, JuvenileAlfasigma · NCT06222034 · 9 enrolled · France, Germany, Poland and more
  13. Mar 4, 2025Phase 3 study in Colitis, UlcerativeAlfasigma · NCT06865417 · 80 planned · Belgium, Croatia, France and more
  14. Apr 15, 20262 phase 3 studies in Arthritis, JuvenileAlfasigma · NCT07554495, NCT07553182

Ahead

  1. Jun 2027Primary completion: phase 3 study in Arthritis, JuvenileAlfasigma · NCT07554495
  2. Dec 2027Primary completion: phase 3 study in Arthritis, JuvenileAlfasigma · NCT07553182
  3. Jun 2028Primary completion: phase 3 study in Colitis, UlcerativeAlfasigma · NCT06865417

TargetBeta

“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
delgocitinibruleLEO Pharmaphase 321

Studies

All 46 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07553182Arthritis, Juvenile · France, Germany, United Kingdom3RecruitingAlfasigmaDec 202780
NCT07554495Arthritis, Juvenile · Belgium, Czechia, France and more3RecruitingAlfasigmaJun 202765
NCT06865417Colitis, Ulcerative · Belgium, Croatia, France and more3RecruitingAlfasigmaJun 202880
NCT06222034Arthritis, Juvenile · France, Germany, Poland and more1TerminatedAlfasigmaJun 17, 20269
NCT06043739Bioavailability · Canada1CompletedLakefront Biotherapeutics NVOct 27, 202312
NCT05785611Axial Spondyloarthritis · Belgium, Bulgaria, Czechia and more3Active, not recruitingAlfasigmaSep 4, 2024495
NCT05479058Colitis, Ulcerative · United States, Belgium, Czechia and more3TerminatedLakefront Biotherapeutics NVOct 9, 202322
NCT04608344Arthritis, Rheumatoid · United States1CompletedGilead SciencesJan 13, 202127
NCT04483700Spondylitis, Ankylosing3WithdrawnGilead SciencesOct 20220
NCT04483687Spondylitis, Ankylosing3WithdrawnGilead SciencesJan 20230
NCT04115839Arthritis, Psoriatic · United States, Australia, Belgium and more3TerminatedGilead SciencesJan 4, 2021106
NCT04115748Arthritis, Psoriatic · United States, Australia, Bulgaria and more3TerminatedGilead SciencesJan 19, 202167
NCT03926195Arthritis, Rheumatoid · Bulgaria, Czechia, Estonia and more2CompletedLakefront Biotherapeutics NVAug 14, 2020109
NCT03417778Arthritis, Rheumatoid · United States, Germany, New Zealand1CompletedGilead SciencesAug 9, 201820
NCT03320876Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more2TerminatedLakefront Biotherapeutics NVJun 30, 2021122
NCT03285711Lupus Membranous Nephropathy · United States2CompletedGilead SciencesMay 3, 20199
NCT03207815Noninfectious Uveitis · United States, Australia, Canada and more2TerminatedGilead SciencesDec 29, 202074
NCT03201445Inflammatory Bowel Diseases · United States, Australia, Austria and more2TerminatedLakefront Biotherapeutics NVNov 20, 2020139
NCT03134222Lupus Erythematosus, Cutaneous · United States, Canada2CompletedGilead SciencesMar 13, 201947
NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more2CompletedGilead SciencesJan 10, 2019152
NCT03117270Spondylitis, Ankylosing · Belgium, Bulgaria, Czechia and more2CompletedLakefront Biotherapeutics NVJul 2, 2018116
NCT03101670Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more2CompletedLakefront Biotherapeutics NVMar 12, 2018131
NCT03077412Fistulizing Crohn's Disease · United States, Austria, Belgium and more2CompletedGilead SciencesJan 20, 202157
NCT03046056Small Bowel Crohn's Disease · United States, Austria, Belgium and more2CompletedGilead SciencesJul 20, 202078
NCT03025308Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedAlfasigmaMay 16, 20252,731
NCT02914600Crohn Disease · United States, Argentina, Australia and more3TerminatedLakefront Biotherapeutics NVAug 1, 20231,188
NCT02914561Crohn Disease · United States, Argentina, Australia and more3CompletedLakefront Biotherapeutics NVNov 11, 20221,372
NCT02914535Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedAlfasigmaSep 8, 20261,173
NCT02914522Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedGilead SciencesMar 31, 20201,351
NCT02889796Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedGilead SciencesJul 4, 20181,759
NCT02886728Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedGilead SciencesOct 5, 20181,252
NCT02873936Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedGilead SciencesMar 20, 2018449
NCT02162355Healthy · United Kingdom1CompletedLakefront Biotherapeutics NVSep 201436
NCT02084199Renal Insufficiency · Germany1CompletedLakefront Biotherapeutics NVJul 201424
NCT02065700Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedLakefront Biotherapeutics NVJan 19, 2023739
NCT02048618Crohn Disease · Belgium, Czech Republic, France and more2CompletedLakefront Biotherapeutics NVNov 2015175
NCT01915667Healthy · Belgium1CompletedLakefront Biotherapeutics NVSep 201312
NCT01894516Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedLakefront Biotherapeutics NVMar 5, 2015287
NCT01888874Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedLakefront Biotherapeutics NVFeb 18, 2015599
NCT01820806Healthy · United Kingdom1CompletedLakefront Biotherapeutics NVApr 20136
NCT01798979Healthy · United States1CompletedLakefront Biotherapeutics NVApr 201320
NCT01668641Arthritis, Rheumatoid · Hungary, Moldova, Republic of, Russian Federation and more2CompletedLakefront Biotherapeutics NVSep 201291
NCT01665924Healthy · Belgium1CompletedLakefront Biotherapeutics NVSep 201236
NCT01419990Healthy · Belgium1CompletedLakefront Biotherapeutics NVOct 201116
NCT01384422Arthritis, Rheumatoid · Moldova, Republic of2CompletedLakefront Biotherapeutics NVNov 201136
NCT01179581Healthy · Belgium1CompletedLakefront Biotherapeutics NVMar 201148

How it is read

Names in the registry

  • “Filgotinib”, 32 entries
  • “GLPG0634”, 11 entries
  • “filgotinib”, 3 entries
  • “GLPG0634 50 mg”, 1 entry
  • “GLPG0634 100 mg”, 1 entry

Codes read as this program: GLPG0634.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.